Therapeutic Effects of Fuzhenghuayu Capsule Combined with Adefovir Dipivoxil on Liver Fibrosis in Patients with Chronic Hepatitis B

Objective To observe the therapeutic effects of Fuzhenghuayu capsule combined with adefovir dipivoxil on liver fibrosis in patients with chronic hepatitis B(CHB).Methods 50 patients with hepatic fibrosis of CHB were selected and divided randomly into treatment group(Fuzhenghuayu capsule combined with adefovir dipivoxil) and control group(adefovir dipivoxil alone).Before and after treatment for 48 weeks,the symptoms,physical signs,parameters of liver function,HBV DNA,HBeAg and hepatic fibrosis parameters were detected for the patients of both groups.Based on the evaluative standards by non-traumatic indexes,the therapeutic effects on liver fibrosis were evaluated.Results After 48 weeks of treatment,the symptoms and signs of the patients in both groups were all significantly improved compared with pretherapy.There was no significant difference in the rates of ALT normalization,HBV DNA negative conversion or HBeAg seroconversion between treatment group and control group(P0.05).However,the decrease of hepatic fibrosis parameter and the improvement of portal vein diameter and spleen thickness in the patients of treatment group were all significantly better than the patients of control group(P0.05).No obvious adverse effects were found during treatment in both groups.Conclusion Treatment chronic hepatitis B with Fuzhenghuayu capsule combined with Adefovir dipivoxil was superior to other methods.